Departments of Periodontics,1 Immunology,2 Medicinal Chemistry, University of Washington, Seattle, Washington3
Received 12 March 2004/ Returned for modification 19 April 2004/ Accepted 26 May 2004
| ABSTRACT |
|---|
|
|
|---|
| INTRODUCTION |
|---|
|
|
|---|
A well-characterized innate host recognition pathway is that for Escherichia coli LPS, which starts with a series of initial binding and transfer reactions between LPS binding protein (LBP), CD14, and other host proteins (49, 64). CD14 is located in the cell membrane of certain host cells (mCD14) and is also present in serum (sCD14) and gingival crevicular fluid, a serum exudate (28, 45). Transfer of E. coli LPS by either mCD14 or sCD14 to a cell-associated Toll-like receptor 4 (TLR4) and MD-2 protein complex (15, 40) initiates host cell activation pathways, leading to innate host defense mediator production.
In the periodontium, innate host responses to microbial colonization are important in both health and disease (14, 59). In clinically healthy periodontal tissue, the highly orchestrated expression of select innate host defense mediators is believed to be associated with commensal microbial colonization (59). These mediators facilitate neutrophil transit through this tissue and into the gingival crevice, where they play a key role in the prevention of disease (24). Periodontitis is an inflammatory disease that is characterized by loss of alveolar bone supporting the tooth root and is the leading cause for tooth loss. Strong evidence for the role of the innate host response to microbial colonization in periodontitis comes from the observation that removal of the dental plaque microbial biofilm remains the most effective treatment for the disease (14). Although the microbial composition of dental plaque associated with health and periodontitis is well characterized (66), little is known about how these different compositions influence the inflammatory response.
Porphyromonas gingivalis is a gram-negative bacterium that is an important etiologic agent of human adult-type periodontitis (54). This bacterium releases copious amounts of outer membrane vesicles containing LPS (19, 20), which can penetrate periodontal tissue (38, 39, 50) and thus participate in the destructive innate host response associated with disease. The potential contribution of P. gingivalis LPS to the disease process is not clear, however, due to complex innate host responses to this cell wall component (4). P. gingivalis LPS is able to activate human monocytes by a CD14-dependent mechanism (51) and binds sCD14 (9); however, it does not facilitate sCD14-dependent E-selectin expression nor interleukin-8 (IL-8) secretion from human umbilical cord vein vascular endothelial cells (11). In fact, this LPS is a natural antagonist for the human endothelial E-selectin and IL-8 responses to E. coli LPS and other oral bacteria (11) and has recently been reported to be a TLR4 antagonist in some cell types (8, 10, 68). Furthermore, although several reports have demonstrated that this LPS utilizes TLR2 instead of TLR4 for host cell activation (5, 26, 37), it has also been reported to engage TLR4 (42, 57) to facilitate gingival fibroblast activation through mCD14 (46, 62).
In this report it is shown that a P. gingivalis LPS preparation enriched for two major lipid A mass ions at m/z 1,435 and 1,450 activates both human and mouse TLR2 and TLR2 plus TLR1, as well as TLR4 in transiently transfected HEK 293 cells coexpressing mCD14. In addition, with the use of primary bone marrow cells obtained from TLR knockout mice, it is shown that this LPS preparation exclusively utilizes either mouse TLR2 or TLR4 to induce tumor necrosis factor alpha (TNF-
) production. The ability of a P. gingivalis LPS preparation to activate cells through multiple TLRs helps to reconcile previous possible conflicting observations that have demonstrated that P. gingivalis LPS preparations can activate either TLR2 or TLR4.
| MATERIALS AND METHODS |
|---|
|
|
|---|
H-2250], 0.005 g/liter; cysteine, 0.4 g/liter; and vitamin K [
M-5625], 0.001 g/liter). Stationary-phase cells were employed for LPS isolation. Purification and characterization of LPS. P. gingivalis LPS was prepared by the cold MgCl2-ethanol (EtOH) procedure (13) followed by lipid extraction (18) and conversion to sodium salts (43). E. coli 0111:B4 LPS (Sigma, St. Louis, Mo.) was subjected to a Folch extraction (18) to remove contaminating phospholipids. All LPS preparations were further treated to remove trace amounts of endotoxin protein as described by Manthey and Vogel (36) with the following modification. Following the final EtOH precipitation, LPS was lyophilized to determine the yield and was resuspended in distilled water to 1 mg/ml without the addition of triethanolamine. LPS was subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and stained for protein by the enhanced colloidal gold procedure, as described in reference 36. The stain was able to detect 100 pg of protein, employing bovine serum albumin as a standard. The presence of nucleic acid was determined by ethidium bromide fluorescence quantification of the amount of double-stranded DNA by using the plastic wrap method (35) and ImageQuant software. The P. gingivalis LPS preparation shown in Fig. 1A was obtained with the use of TRI reagent as previously described (67).
|
Matrix assisted laser desorption-time-of-flight (MALDI-TOF) MS was performed as previously described (21). Two separate extractions of P. gingivalis LPS were produced and analyzed.
Cells and reagents.
Human embryonic kidney (HEK) 293 cells were maintained in Dulbecco's modified Eagle's medium (GibcoBRL, Rockville, Md.) with 10% heat-inactivated fetal calf serum (HyClone, Logan, Utah). The NF-
B reporter construct (ELAM-1 firefly luciferase), the ß-actin-Renilla luciferase reporter construct, the modified pDisplay expression vector, and the expression constructs for murine TLR2 (pmuTLR2), murine TLR1 (pmuTLR1), murine TLR4 (pmuTLR4), and human TLR4 (phuTLR4) and mCD14 (phumCD14) have been described previously (22, 23). Human TLR1 (phuTLR1) and TLR2 (phuTLR2) open reading frames were cloned into the modified pDisplay expression vector. The human and murine MD-2 plasmids were kindly provided by Kensuke Miyake (The University of Tokyo, Tokyo, Japan). CD14-depleted serum was prepared as described previously (9).
Luciferase assays. HEK 293 cells were transfected by calcium phosphate precipitation and stimulated as described previously (23) with the modifications reported for a 96-well plate assay format (22). Cells were washed twice with medium 3 h after transfection and stimulated 20 to 24 h posttransfection. Stimulations were performed in stimulation medium (Dulbecco's modified Eagle's medium containing 10% fetal bovine serum (FBS), 10% human serum, or sCD14-depleted normal human serum) for 4 h at 37°C, using concentrations of ligands as indicated below in the text and figure legends. After stimulation, cells were rinsed with phosphate-buffered saline (BioWhittaker, Walkersville, Md.) and lysed with 50 µl of passive lysis buffer (Promega, Madison, Wis.). Reporter gene expression in each lysate (10 µl) was measured using the Dual Luciferase reporter assay system (Promega). Data are expressed as the fold increase in relative light units (which represents the ratio of ELAM-luciferase to ß-actin Renilla-luciferase expression) relative to that of a no-stimulation control. All experiments were performed a minimum of three separate times with similar results. Results from one experiment performed with data from triplicate wells are presented.
Stimulation of primary bone marrow cells obtained from TLR knockout mice.
TLR2/ and TLR4/ mice were backcrossed for six generations to C57BL/6 mice and then intercrossed to obtain TLR2/4 double-knockout mice. Bone marrow cells were isolated from femurs and tibias of mice bred at the University of Washington. Following red cell lysis, 1 x 106 to 2 x 106 cells were plated per well in round-bottom 96-well plates. The cells were stimulated with concentrations of ligands as indicated below in the text and figure legends for 5 h in the presence of GolgiStop (Pharmingen). Cells were then stained for surface expression of CD11b (Pharmingen), permeabilized with Cytoperm/Cytofix (Pharmingen), and stained for intracellular TNF-
(Caltag). Cells were analyzed on a Becton Dickinson FACScan flow cytometer using CellQuest software (BD Biosciences).
| RESULTS |
|---|
|
|
|---|
In this report, the degree and extent of P. gingivalis LPS lipid A heterogeneity was examined with the use of a new crude LPS extraction procedure which employs commercially available TRI reagent (67). It was found that P. gingivalis LPS contains more major lipid A mass ions than previously described (Fig. 1A) and that the MgCL2-EtOH LPS purification procedure failed to extract all of the different lipid A mass ions equally (Fig. 1B). TRI reagent extraction of LPS from P. gingivalis and subsequent lipid A cleavage (7) revealed numerous major lipid A mass ions that clustered around m/z 1,450, 1,690, and 1,770. The lipid A species found clustered around each of these mass ions differed by smaller single methylene units (m/z 1,420 and 1,435 adjacent to 1,450; 1,675 adjacent to 1,690; and 1,705 and 1,755 adjacent to 1,770) and larger single methylene units (m/z 1,465 and 1,480 adjacent to 1,450; 1,705 adjacent to 1,690; and 1,785 and 1,800 adjacent to 1,770). This pattern of different lipid A mass ions is indicative of fatty acid chain length heterogeneity, accounting for some of the different lipid A species. In contrast, LPS extracted from whole cells by the MgCl2-EtOH method was significantly reduced in both clusters of lipid A mass ions centered at m/z 1,690 and m/z 1,770. This preparation, designated Pg LPS1435/1450 (see below), revealed major lipid A mass ions at m/z 1,435 and 1,450 (Fig. 1B); the structures for both of these P. gingivalis lipid A species have been previously elucidated (32) (Fig. 2). In addition, two minor peaks at m/z 1,420 and 1,465 were observed and are suspected to represent structurally related lipid A mass ions that differ in their fatty acid content.
|
Characterization of the P. gingivalis LPS preparation employed to examine TLR utilization. The MgCl2-EtOH LPS preparation was characterized with respect to possible contaminants that could interfere with the TLR utilization studies. In particular, bacterial lipoproteins that remain tightly associated with LPS during purification have been shown to utilize TLR2 (34). The P. gingivalis LPS preparation obtained by the cold MgCl2-EtOH procedure was further treated to remove trace amounts of endotoxin protein as described by Manthey and Vogel (36). Similar to our group's previous results (3), colloidal gold staining (to detect protein) of the P. gingivalis LPS preparations before and after phenol extraction revealed that protein was removed from the MgCl2-ETOH P. gingivalis LPS preparation (designated Pg0 in Fig. 3) to yield a highly purified Pg LPS1435/1450 preparation (Fig. 3). Determination of the relative amount of protein contamination by comparison to known bovine serum albumin standards (based upon the amount of LPS loaded into the gel and the relative intensity of the major protein band) revealed between 0.1 and 1% protein in the P. gingivalis LPS preparation before extraction and less than 0.1% protein contamination in the extracted Pg LPS1435/1450 preparation.
|
P. gingivalis LPS enriched in lipid A mass ions of m/z 1,435 and 1,450 activates HEK cells through TLR2, TLR2 plus TLR1, and TLR4.
The ability of the Pg LPS1435/1450 P. gingivalis preparation to activate cells through specific TLRs was examined by employing HEK cell transient transfections with different components of the TLR2 and TLR4 activation complexes. Initially, a control experiment was performed to determine if endogenous receptors on HEK cells were capable of responding to the P. gingivalis LPS preparation. HEK cells were cotransfected with the control plasmid (ß-actin-Renilla luciferase) and the NF-
B-dependent reporter plasmid (ELAM-firefly luciferase), and various concentrations of Pg LPS1435/1450 were added. This LPS preparation did not significantly induce the reporter construct, validating HEK 293 cells as a suitable cell line to examine the interactions of P. gingivalis LPS with different exogenously added TLRs (data not shown). Therefore, experiments described below report the ability of the Pg LPS1435/1450 preparation to activate HEK cells above background levels and compare Pg LPS1435/1450 activation to that of known TLR ligands.
The abilities of the Pg LPS1435/1450 preparation and the synthetic lipopeptide (Pam3CSK4), a known TLR2 agonist (1), to stimulate HEK 293 cells transiently transfected with human TLR2 (huTLR2) were determined (Fig. 4A and B). In these experiments, HEK cells were transfected with human mCD14 with and without MD-2, components of the innate host response known to optimize LPS interactions with TLRs (16, 52, 64). P. gingivalis LPS significantly (P < 0.001; two-sample t test) activated HEK cells through huTLR2 (an eightfold increase at 1 µg of LPS/ml, with or without the addition of MD-2), although it was significantly (P < 0.001; two-sample test) less active than Pam3CSK4 (Fig. 4A and B). Additional experiments employing murine TLR2 (muTLR2) with murine MD-2 also demonstrated significant HEK cell activation (P < 0.001; two-sample t test) that was significantly (P < 0.001; two-sample t test) less than that with Pam3CSK4 (data not shown).
|
The Pg LPS1435/1450 preparation was compared to E. coli LPS, a known TLR4 ligand (15, 40, 44), in its ability to stimulate HEK 293 cells transiently transfected with either muTLR4 or huTLR4 (Fig. 5). HEK cells transfected with mouse or human mCD14 and either muTLR4 and muMD-2 (Fig. 5A) or huTLR4 and huMD-2 (Fig. 5B) (either all mouse or all human components) displayed significant increases in activation in response to E. coli or P. gingivalis LPS preparations (P < 0.001; two-sample t test for concentrations of 100 and 1,000 ng of LPS/ml). However, the P. gingivalis LPS preparation required considerably more LPS to achieve significant activation than the E. coli LPS. For example, in Fig. 5A, E. coli LPS demonstrated significantly greater-than-fivefold HEK cell activation at 0.1 ng/ml (P < 0.001; two-sample t test). Both mouse and human TLR4-dependent HEK cell activation in response to E. coli or P. gingivalis LPS was MD-2 dependent (Fig. 5C and D), consistent with the previously reported key role of this protein in TLR4 LPS responses (40, 52). These data demonstrate that highly purified preparations of P. gingivalis LPS are capable of signaling via TLR2, TLR2 plus TLR1, and TLR4.
|
|
P. gingivalis LPS enriched in lipid A mass ions of m/z 1,435 and 1,450 activates primary bone marrow cells obtained from both TLR2 and TLR4 knockout mice.
The HEK transient-transfection experiments with either TLR2 or TLR4 demonstrated that the Pg LPS1435/1450 preparation was able to engage either TLR receptor to activate the NF-
B-dependent reporter construct. The ability of this P. gingivalis LPS preparation to activate mouse bone marrow cells obtained from TLR2/, TLR4/, and TLR2/4/ knockout mice was examined in order to determine if endogenous TLR2 and TLR4 were utilized. Activation was determined by intracellular TNF-
staining and fluorescence-activated cell sorter analysis (Fig. 7). It was found that bone marrow cells obtained from either TLR2/ or TLR4/ mice responded to the Pg LPS1435/1450 preparation. These data are consistent with the observations made in HEK cells that demonstrated this P. gingivalis LPS preparation could utilize either TLR2 or TLR4 for host cell activation. Furthermore, cells obtained from TLR2/4 double-knockout mice did not respond to the P. gingivalis LPS preparation, demonstrating that the LPS activity observed with this cell type was mediated exclusively through TLR2 and TLR4. In contrast, bone marrow cell responses to Salmonella minnesota LPS (a TLR4 ligand) and Pam3CSK4 (a TLR2 ligand) demonstrated that these microbial ligands utilized their respective cognate TLR. These data provide good evidence that P. gingivalis LPS can utilize TLR2 and TLR4 under conditions where they are expressed at endogenous levels.
|
| DISCUSSION |
|---|
|
|
|---|
The biological significance of the multiple lipid A species found in P. gingivalis LPS preparations is not currently understood. A preliminary examination has revealed that several different P. gingivalis laboratory strains and clinical isolates display a similar pattern of lipid A heterogeneity as that shown in this work, demonstrating that the major lipid A mass ions are not strain specific (data not shown). Several other bacterial species have been shown to contain multiple lipid A forms that exist in a single bacterial population (2, 47, 48, 53, 58) and that can be regulated by incubation temperature (29) or the concentration of Mg2+ in the growth medium (17). In Salmonella enterica serovar Typhimurium, additional lipid A species that alter the human endothelial cell response of purified LPS have been shown to be under the control of a phoP/phoQ two-component regulatory system (21). Similarly, P. gingivalis may also synthesize multiple lipid A species, accounting for the heterogeneity observed in purified LPS preparations (5, 32). Conversely, P. gingivalis lipid A heterogeneity may arise due to isolation and characterization procedures. For example, isolation of LPS often involves heating in phenol, and examination of lipid A requires acid hydrolysis of the lipid A from the 3-deoxy-D-manno-octulosonic acid core sugar, and these procedures may result in cleavage of acid-labile fatty acids and phosphate residues. However, our laboratory has found that P. gingivalis LPS preparations contain the 1,435 and 1,450 lipid A species as the major peaks in MALDI-TOF analysis when either the phenol-water (63) or MgCl2 LPS (13) extraction procedures are employed or if the LPS is subjected to two different lipid A hydrolysis procedures (7, 41) (data not shown). This strongly suggests that the lipid A mass ions found at m/z 1,435 and 1,450 did not arise due to the type of LPS extraction or lipid A hydrolysis procedures. Additional studies will be required to determine the origin of P. gingivalis lipid A heterogeneity; nevertheless, it is clear that purified P. gingivalis LPS preparations may contain more than one lipid A species, and this may account for the discrepancy in host cell activation assays observed between chemically synthesized lipid As and native highly purified preparations.
Transient HEK cell transfection experiments provide an excellent means to determine the components of the TLR complex necessary to facilitate host cell responses. In this report, it was found that MD-2 was not required for P. gingivalis LPS TLR2-dependent, or TLR2-plus-TLR1-dependent, HEK cell activation but was necessary for activation with mouse or human TLR4. It is interesting that in another HEK system, endogenous levels of MD-2 were sufficient to facilitate TLR4 E. coli LPS activation (16). This may explain why in a study employing transiently transfected HEK cells (where the endogenous levels of MD-2 were not reported), TLR4-dependent cell activation with phenol-extracted P. gingivalis LPS was not observed (26). The requirement for different TLR cofactors for cell stimulation is consistent with other observations (16, 40, 61) that have shown each bacterial ligand may require different components of the TLR signaling complex to facilitate host cell activation.
Furthermore, sCD14 amply replaced mCD14 to yield highly significant P. gingivalis LPS TLR2-plus-TLR1-dependent HEK cell activation, as demonstrated both by significant activation at low LPS concentrations (10 ng/ml) and a greater-than-15-fold increase over background at higher concentrations of LPS. However, huTLR4-dependent HEK cell activation employing sCD14 revealed that the Pg LPS1435/1450 preparation only slightly activated these cells above background control levels at 100 and 1,000 ng of LPS/ml. These data demonstrate that the TLR activity of P. gingivalis LPS preparations is particularly prone to the presence of key accessory molecules, such as soluble or membrane CD14. In addition, it has previously been shown that P. gingivalis LPS can utilize hamster but not human TLR4 when combined with endogenous hamster MD-2 (68), further emphasizing that P. gingivalis LPS-dependent host cell activation, in contrast to that with E. coli LPS, is more sensitive to the species specificity of the TLR complex components. These factors, combined with the potential for multiple lipid A species in P. gingivalis LPS preparations, almost certainly have contributed to the variability reported for TLR utilization by P. gingivalis LPS.
One implication of the work presented here is that P. gingivalis LPS may activate host cells through either a TLR2- or TLR4-dependent pathway. The results of HEK cell transfection assays and bone marrow cell activation experiments demonstrate that certain P. gingivalis LPS preparations have the ability to interact with either TLR2 or TLR4. Another related implication is that the lipid A heterogeneity observed in P. gingivalis LPS preparations may reflect an ability of this bacterium to synthesize and express multiple, structurally different forms of lipid A. Alterations in the lipid A structural composition and utilization of multiple TLRs may affect host cell signaling, contributing to the ability of P. gingivalis to remain a persistent colonizer of the oral cavity as well as to induce inflammatory disease.
| ACKNOWLEDGMENTS |
|---|
This work was supported in part by NIDCR grant DE12768 to R.P.D.
| FOOTNOTES |
|---|
| REFERENCES |
|---|
|
|
|---|
| 1. | Aliprantis, A. O., R. B. Yang, M. R. Mark, S. Suggett, B. Devaux, J. D. Radolf, G. R. Klimpel, P. Godowski, and A. Zychlinsky. 1999. Cell activation and apoptosis by bacterial lipoproteins through toll-like receptor-2. Science 285:736-739. |
| 2. | Aussel, L., J. R. Brisson, M. B. Perry, and M. Caroff. 2000. Structure of the lipid A of Bordetella hinzii ATCC 51730. Rapid Commun. Mass Spectrom. 14:595-599.[CrossRef][Medline] |
| 3. | Bainbridge, B. W., S. R. Coats, and R. P. Darveau. 2002. Porphyromonas gingivalis lipopolysaccharide displays functionally diverse interactions with the innate host defense system. Ann. Periodontol. 7:1-9. |
| 4. | Bainbridge, B. W., and R. P. Darveau. 1997. Lipopolysaccharide from oral bacteria: role in innate host defense and chronic inflammatory disease, p. 899-913. In D. Morrison (ed.), Endotoxin in health and disease. Marcel Dekker, New York, N.Y. |
| 5. | Bainbridge, B. W., and R. P. Darveau. 2001. Porphyromonas gingivalis lipopolysaccharide: an unusual pattern recognition receptor ligand for the innate host defense system. Acta Odontol. Scand. 59:131-138.[CrossRef][Medline] |
| 6. | Beutler, B. 2000. Tlr4: central component of the sole mammalian LPS sensor. Curr. Opin. Immunol. 12:20-26.[CrossRef][Medline] |
| 7. | Caroff, M., A. Tacken, and L. Szabó. 1988. Detergent-accelerated hydrolysis of bacterial endotoxins and determination of the anomeric configuration of the glycosyl phosphate present in the "isolated lipid A" fragment of the Bordetella pertussis endotoxin. Carbohydr. Res. 175:273-282.[CrossRef][Medline] |
| 8. | Coats, S. R., R. A. Reife, B. W. Bainbridge, T. T. Pham, and R. P. Darveau. 2003. Porphyromonas gingivalis lipopolysaccharide antagonizes Escherichia coli lipopolysaccharide at toll-like receptor 4 in human endothelial cells. Infect. Immun. 71:6799-6807. |
| 9. | Cunningham, M. D., C. Seachord, K. Ratcliffe, B. Bainbridge, A. Aruffo, and R. P. Darveau. 1996. Helicobacter pylori and Porphyromonas gingivalis lipopolysaccharides are poorly transferred to recombinant soluble CD14. Infect. Immun. 64:3601-3608.[Abstract] |
| 10. | Darveau, R. P., S. Arbabi, I. Garcia, B. Bainbridge, and R. V. Maier. 2002. Porphyromonas gingivalis lipopolysaccharide is both an agonist and antagonist for p38 mitogen-activated protein kinase activation. Infect. Immun. 70:1867-1873. |
| 11. | Darveau, R. P., M. D. Cunningham, T. Bailey, C. Seachord, K. Ratcliffe, B. Bainbridge, M. Dietsch, R. C. Page, and A. Aruffo. 1995. Ability of bacteria associated with chronic inflammatory disease to stimulate E-selectin expression and promote neutrophil adhesion. Infect. Immun. 63:1311-1317.[Abstract] |
| 12. | Darveau, R. P., M. D. Cunningham, C. L. Seachord, L. Cassiano-Clough, W. L. Cosand, J. Blake, and C. S. Watkins. 1991. ß-Lactam antibiotics potentiate magainin 2 antimicrobial activity in vitro and in vivo. Antimicrob. Agents Chemother. 35:1153-1159. |
| 13. | Darveau, R. P., and R. E. Hancock. 1983. Procedure for isolation of bacterial lipopolysaccharides from both smooth and rough Pseudomonas aeruginosa and Salmonella typhimurium strains. J. Bacteriol. 155:831-838. |
| 14. | Darveau, R. P., A. Tanner, and R. C. Page. 1997. The microbial challenge in periodontitis. Periodontology 2000 14:12-32.[Medline] |
| 15. | da Silva Correia, J., K. Soldau, U. Christen, P. S. Tobias, and R. J. Ulevitch. 2001. Lipopolysaccharide is in close proximity to each of the proteins in its membrane receptor complex. Transfer from CD14 to TLR4 and MD-2. J. Biol. Chem. 276:21129-21135. |
| 16. | Dziarski, R., Q. Wang, K. Miyake, C. J. Kirschning, and D. Gupta. 2001. MD-2 enables Toll-like receptor 2 (TLR2)-mediated responses to lipopolysaccharide and enhances TLR2-mediated responses to gram-positive and gram-negative bacteria and their cell wall components. J. Immunol. 166:1938-1944. |
| 17. | Ernst, R. K., E. C. Yi, L. Guo, K. B. Lim, J. L. Burns, M. Hackett, and S. I. Miller. 1999. Specific lipopolysaccharide found in cystic fibrosis airway Pseudomonas aeruginosa. Science 286:1561-1565. |
| 18. | Folch, J., M. Lees, and G. H. S. Stanley. 1957. A simple method for the isolation and purification of total lipids from animal tissues. J. Biol. Chem. 226:497-509. |
| 19. | Grenier, D., J. Bertrand, and D. Mayrand. 1995. Porphyromonas gingivalis outer membrane vesicles promote bacterial resistance to chlorhexidine. Oral Microbiol. Immunol. 10:319-320.[Medline] |
| 20. | Grenier, D., and D. Mayrand. 1987. Functional characterization of extracellular vesicles produced by Bacteroides gingivalis. Infect. Immun. 55:111-117. |
| 21. | Guo, L., K. B. Lim, J. S. Gunn, B. Bainbridge, R. P. Darveau, M. Hackett, and S. I. Miller. 1997. Regulation of lipid A modifications by Salmonella typhimurium virulence genes, phoP-phoQ. Science 276:250-253. |
| 22. | Hajjar, A. M., R. K. Ernst, J. H. Tsai, C. B. Wilson, and S. I. Miller. 2002. Human Toll-like receptor 4 recognizes host-specific LPS modifications. Nat. Immunol. 3:354-359.[CrossRef][Medline] |
| 23. | Hajjar, A. M., D. S. O'Mahony, A. Ozinsky, D. M. Underhill, A. Aderem, S. J. Klebanoff, and C. B. Wilson. 2001. Cutting edge: functional interactions between Toll-like receptor (TLR) 2 and TLR1 or TLR6 in response to phenol-soluble modulin. J. Immunol. 166:15-19. |
| 24. | Hart, T. C., L. Shapira, and T. E. Van Dyke. 1994. Neutrophil defects as risk factors for periodontal diseases. J. Periodontol. 65:521-529.[Medline] |
| 25. | Haziot, A., N. Hijiya, S. C. Gangloff, J. Silver, and S. M. Goyert. 2001. Induction of a novel mechanism of accelerated bacterial clearance by lipopolysaccharide in CD14-deficient and Toll-like receptor 4-deficient mice. J. Immunol. 166:1075-1078. |
| 26. | Hirschfeld, M., J. J. Weis, V. Toshchakov, C. A. Salkowski, M. J. Cody, D. C. Ward, N. Qureshi, S. M. Michalek, and S. N. Vogel. 2001. Signaling by toll-like receptor 2 and 4 agonists results in differential gene expression in murine macrophages. Infect. Immun. 69:1477-1482. |
| 27. | Janeway, C. J. 1992. The immune system evolved to discriminate infectious nonself from noninfectious self. Immunol. Today 13:11-16.[CrossRef][Medline] |
| 28. | Jin, L., and R. P. Darveau. 2001. Soluble CD14 levels in gingival crevicular fluid of subjects with untreated adult periodontitis. J. Periodontol. 72:634-640.[CrossRef][Medline] |
| 29. | Kawahara, K., H. Tsukano, H. Watanabe, B. Lindner, and M. Matsuura. 2002. Modification of the structure and activity of lipid A in Yersinia pestis lipopolysaccharide by growth temperature. Infect. Immun. 70:4092-4098. |
| 30. | Khan, S. A., P. Everest, S. Servos, N. Foxwell, U. Zahringer, H. Brade, E. T. Rietschel, G. Dougan, I. G. Charles, and D. J. Maskell. 1998. A lethal role for lipid A in Salmonella infections. Mol. Microbiol. 29:571-579.[CrossRef][Medline] |
| 31. | Kopp, E. B., and R. Medzhitov. 1999. The Toll-receptor family and control of innate immunity. Curr. Opin. Immunol. 11:13-18.[CrossRef][Medline] |
| 32. | Kumada, H., Y. Haishima, T. Umemoto, and K.-I. Tanamoto. 1995. Structural study on the free lipid A isolated from lipopolysaccharide of Porphyromonas gingivalis. J. Bacteriol. 177:2098-2106. |
| 33. | Kumada, H., T. Umemoto, K. Watanabe, H. Tamura, T. Murai, Y. Nakagawa, K.-I. Tanamoto, and Y. Haishima. 2002. Biological properties of the native and synthetic lipid A of Porphyromonas gingivalis lipopolysaccharide. J. Dent. Res. 81:A-197. |
| 34. | Lee, H. K., J. Lee, and P. S. Tobias. 2002. Two lipoproteins extracted from Escherichia coli K-12 LCD25 lipopolysaccharide are the major components responsible for Toll-like receptor 2-mediated signaling. J. Immunol. 168:4012-4017. |
| 35. | Maniatis, T., E. F. Fritsch, and J. Sambrook. 1982. Molecular cloning: a laboratory manual, p. 468-492. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. |
| 36. | Manthey, C. L., and S. N. Vogel. 1994. Elimination of trace endotoxin protein from rough chemotype LPS. J. Endotoxin Res. 1:84-91. |
| 37. | Martin, M., J. Katz, S. N. Vogel, and S. M. Michalek. 2001. Differential induction of endotoxin tolerance by lipopolysaccharides derived from Porphyromonas gingivalis and Escherichia coli. J. Immunol. 167:5278-5285. |
| 38. | McCoy, S. A., H. R. Creamer, M. Kawanami, and D. F. Adams. 1987. The concentration of lipopolysaccharide on individual root surfaces at varying times following in vivo root planing. J. Periodontol. 58:393-399.[Medline] |
| 39. | Moore, J., M. Wilson, and J. B. Kieser. 1986. The distribution of bacterial lipopolysaccharide (endotoxin) in relation to periodontally involved root surfaces. J. Clin. Periodontol. 13:748-751.[CrossRef][Medline] |
| 40. | Muta, T., and K. Takeshige. 2001. Essential roles of CD14 and lipopolysaccharide-binding protein for activation of toll-like receptor (TLR)2 as well as TLR4. Reconstitution of TLR2- and TLR4-activation by distinguishable ligands in LPS preparations. Eur. J. Biochem. 268:4580-4589.[Medline] |
| 41. | Ogawa, T. 1993. Chemical structure of lipid A from Porphyromonas (Bacteroides) gingivalis lipopolysaccharide. FEBS Lett. 332:197-201.[CrossRef][Medline] |
| 42. | Ogawa, T., Y. Asai, M. Hashimoto, O. Takeuchi, T. Kurita, Y. Yoshikai, K. Miyake, and S. Akira. 2002. Cell activation by Porphyromonas gingivalis lipid A molecule through Toll-like receptor 4- and myeloid differentiation factor 88-dependent signaling pathway. Int. Immunol. 14:1325-1332. |
| 43. | Peterson, A. A., A. Haug, and E. J. McGroarty. 1986. Physical properties of short- and long-O-antigen-containing fractions of lipopolysaccharide from Escherichia coli O111:B4. J. Bacteriol. 165:116-122. |
| 44. | Poltorak, A., P. Ricciardi-Castagnoli, S. Citterio, and B. Beutler. 2000. Physical contact between lipopolysaccharide and toll-like receptor 4 revealed by genetic complementation. Proc. Natl. Acad. Sci. USA 97:2163-2167. |
| 45. | Pugin, J., C.-C. Schürer-Maly, D. Leturcq, A. Moriarty, R. J. Ulevitch, and P. S. Tobias. 1993. Lipopolysaccharide activation of human endothelial and epithelial cells is mediated by lipopolysaccharide-binding protein and soluble CD14. Proc. Natl. Acad. Sci. USA 90:2744-2748. |
| 46. | Putnins, E. E., A.-R. Sanaie, Q. Wu, and J. D. Firth. 2002. Induction of keratinocyte growth factor 1 expression by lipopolysaccharide is regulated by CD14 and Toll-like receptors 2 and 4. Infect. Immun. 70:6541-6548. |
| 47. | Que, N. L., S. Lin, R. J. Cotter, and C. R. Raetz. 2000. Purification and mass spectrometry of six lipid A species from the bacterial endosymbiont Rhizobium etli. Demonstration of a conserved distal unit and a variable proximal portion. J. Biol. Chem. 275:28006-28016. |
| 48. | Rund, S., B. Lindner, H. Brade, and O. Holst. 1999. Structural analysis of the lipopolysaccharide from Chlamydia trachomatis serotype L2. J. Biol. Chem. 274:16819-16824. |
| 49. | Schumann, R. R., S. R. Leong, G. W. Flaggs, P. W. Gray, S. D. Wright, J. C. Mathison, P. S. Tobias, and R. J. Ulevitch. 1990. Structure and function of lipopolysaccharide binding protein. Science 249:1429-1431. |
| 50. | Schwartz, J., F. L. Stinson, and R. B. Parker. 1972. The passage of tritiated bacterial endotoxin across intact gingival crevicular epithelium. J. Periodontol. 43:270-276.[Medline] |
| 51. | Shapira, L., S. Takashiba, S. Amar, and T. E. Van Dyke. 1994. Porphyromonas gingivalis lipopolysaccharide stimulation of human monocytes: dependence on serum and CD14 receptor. Oral Microbiol. Immunol. 9:112-117.[Medline] |
| 52. | Shimazu, R., S. Akashi, H. Ogata, Y. Nagai, K. Fukudome, K. Miyake, and M. Kimoto. 1999. MD-2, a molecule that confers lipopolysaccharide responsiveness on Toll-like receptor 4. J. Exp. Med. 189:1777-1782. |
| 53. | Silipo, A., R. Lanzetta, A. Amoresano, M. Parrilli, and A. Molinaro. 2002. Ammonium hydroxide hydrolysis: a valuable support in the MALDI-TOF mass spectrometry analysis of lipid A fatty acid distribution. J. Lipid Res. 43:2188-2195. |
| 54. | Socransky, S. S., and A. D. Haffajee. 1992. The bacterial etiology of destructive periodontal disease: current concepts. J. Periodontol. 63:322-331.[Medline] |
| 55. | Somerville, J. E., Jr., L. Cassiano, and R. P. Darveau. 1999. Escherichia coli msbB gene as a virulence factor and a therapeutic target. Infect. Immun. 67:6583-6590. |
| 56. | Somerville, J. E. J., L. Cassiano, B. Bainbridge, M. D. Cunningham, and R. P. Darveau. 1996. A novel Escherichia coli lipid A mutant that produces an antiinflammatory lipopolysaccharide. J. Clin. Investig. 97:359-365.[Medline] |
| 57. | Tabeta, K., K. Yamazaki, S. Akashi, K. Miyake, H. Kumada, T. Umemoto, and H. Yoshie. 2000. Toll-like receptors confer responsiveness to lipopolysaccharide from Porphyromonas gingivalis in human gingival fibroblasts. Infect. Immun. 68:3731-3735. |
| 58. | Therisod, H., M. A. Monteiro, M. B. Perry, and M. Caroff. 2001. Helicobacter mustelae lipid A structure differs from that of Helicobacter pylori. FEBS Lett. 499:1-5.[CrossRef][Medline] |
| 59. | Tonetti, M. S., M. A. Imboden, and N. P. Lang. 1998. Neutrophil migration into the gingival sulcus is associated with transepithelial gradients of interleukin-8 and ICAM-1. J. Periodontol. 69:1139-1147.[Medline] |
| 60. | Ulevitch, R. J., and P. S. Tobias. 1999. Recognition of gram-negative bacteria and endotoxin by the innate immune system. Curr. Opin. Immunol. 11:19-22.[CrossRef][Medline] |
| 61. | Viriyakosol, S., J. C. Mathison, P. S. Tobias, and T. N. Kirkland. 2000. Structure-function analysis of CD14 as a soluble receptor for lipopolysaccharide. J. Biol. Chem. 275:3144-3149. |
| 62. | Wang, P. L., and K. Ohura. 2002. Porphyromonas gingivalis lipopolysaccharide signaling in gingival fibroblastsCD14 and Toll-like receptors. Crit. Rev. Oral Biol. Med. 13:132-142. |
| 63. | Westphal, O., and K. Jann. 1965. Bacterial lipopolysaccharides: extraction with phenol-water and further applications of the procedure, p. 83. In R. Whistler (ed.), Methods in carbohydrate chemistry, vol. 5. Academic Press, Inc., New York, N.Y. |
| 64. | Wright, S. D., R. A. Ramos, P. S. Tobias, R. J. Ulevitch, and J. C. Mathison. 1990. CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein. Science 249:1431-1433. |
| 65. | Wyllie, D. H., E. Kiss-Toth, A. Visintin, S. C. Smith, S. Boussouf, D. M. Segal, G. W. Duff, and S. K. Dower. 2000. Evidence for an accessory protein function for the Toll-like receptor TLR1 in lipopolysaccharide responses. J. Immunol. 165:7125-7132. |
| 66. | Ximenez-Fyvie, L. A., A. D. Haffajee, and S. S. Socransky. 2000. Comparison of the microbiota of supra- and subgingival plaque in health and periodontitis. J. Clin. Periodontol. 27:648-657.[CrossRef][Medline] |
| 67. | Yi, E. C., and M. Hackett. 2000. Rapid isolation method for lipopolysaccharide and lipid A from gram-negative bacteria. Analyst 125:651-656.[CrossRef][Medline] |
| 68. | Yoshimura, A., T. Kaneko, Y. Kato, D. T. Golenbock, and Y. Hara. 2002. Lipopolysaccharides from periodontopathic bacteria Porphyromonas gingivalis and Capnocytophaga ochracea are antagonists for human toll-like receptor 4. Infect. Immun. 70:218-225. |
This article has been cited by other articles: